68. Tanaka N, Asakawa I, Hasegawa M, Fujimoto K. Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in Japan. Int J Urol. 27(1):17-23, 2020

69. Nakai Y, Tanaka N, Asakawa I, Anai S, Miyake M, Morizawa Y, Hori S, Owari T, Fujii T, Yamaki K, Hasegawa M, Fujimoto K. Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone. Jpn J Clin Oncol. 50(1):58-65, 2020

70. Hino Y, Yamada Y, Miura S, Okada F, Uchiyama T, Mabuchi S. Clitoral metastasis from uterine cervical cancer: A case report and review of the literature. Gynecol Oncol Rep. 33:100591, 2020

71. Tsuru S, Tamamoto T, Furuya H, Nakao A, Fukuyama M, Tanizaki K, Yahagi N. Nursing Record Innovations Aimed at Harmonizing Structured Clinical Knowledge Among Doctors and Nurses. Stud Health Technol Inform. 270:638-642, 2020

72. Miyake M, Tanaka N, Asakawa I, Yamaki K, Inoue T, Suzuki S, Hori S, Nakai Y, Anai S, Torimoto K, Toritsuka M, Nakagawa H, Tsukamoto S, Fujii T, Ohbayashi C, Hasegawa M, Kasahara M, Fujimoto K. A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study. Contemp Clin Trials Commun. 19:100593, 2020

73. Eura N, Matsui TK, Luginbühl J, Matsubayashi M, Nanaura H, Shiota T, Kinugawa K, Iguchi N, Kiriyama T, Zheng C, Kouno T, Lan YJ, Kongpracha P, Wiriyasermkul P, Sakaguchi YM, Nagata R, Komeda T, Morikawa N, Kitayoshi F, Jong M, Kobashigawa S, Nakanishi M, Hasegawa M, Saito Y, Shiromizu T, Nishimura Y, Kasai T, Takeda M, Kobayashi H, Inagaki Y, Tanaka Y, Makinodan M, Kishimoto T, Kuniyasu H, Nagamori S, Muotri AR, Shin JW, Sugie K, Mori E. Brainstem Organoids From Human Pluripotent Stem Cells. Front Neurosci. 14:538, 2020

74. Fujitani N, Yoshimine T, Takeda M, Yamaki K, Miura S, Hasegawa M. Applicability of the linear-quadratic model to hypofractionated radiotherapy. J Nara Med Assoc. 71 (1,2,3): 7-15, 2020

75. Matsuda R, Tamamoto T, Sugimoto T, Hontsu S, Yamaki K, Miura S, Takeshima Y, Tamura K, Yamada S, Nishimura F, Nakagawa I, Motoyama Y, Park YS, Nakase H, Hasegawa M. Linac-based fractionated stereotactic radiotherapy with a micro-multileaf collimator for large brain metastasis unsuitable for surgical resection. J Radiat Res. 61(4):546-553, 2020

76. Nakai Y, Tanaka N, Asakawa I, Anai S, Miyake M, Morizawa Y, Hori S, Owari T, Fujii T, Ohbayashi C, Yamaki K, Hasegawa M, Fujimoto K. Biochemical control of the combination of cyclooxygenase-2 inhibitor and 125I-brachytherapy for prostate cancer: Post hoc analysis of an open-label controlled randomized trial. Int J Urol. 27(9):755-759, 2020

77. Ito SS, Nakagawa Y, Matsubayashi M, Sakaguchi YM, Kobashigawa S, Matsui TK, Nanaura H, Nakanishi M, Kitayoshi F, Kikuchi S, Kajihara A, Tamaki S, Sugie K, Kashino G, Takahashi A, Hasegawa M, Mori E, Kirita T. Inhibition of the ATR kinase enhances 5-FU sensitivity independently of nonhomologous end-joining and homologous recombination repair pathways. J Biol Chem. 295(37):12946-12961, 2020

78. Tanaka N, Asakawa I, Nakai Y, Miyake M, Anai S, Yamaki K, Fujii T, Hasegawa M, Fujimoto K. Coverage of the external prostatic region by the hybrid method compared with the conventional method of prostate low-dose-rate brachytherapy: A randomized controlled study. Int J Urol. 27(11):1013-1017, 2020